{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T23:09:18Z","timestamp":1790464158571,"version":"4.1.0"},"reference-count":55,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T00:00:00Z","timestamp":1725926400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000190","name":"University of Alberta","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000190","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Human Vaccines & Immunotherapeutics"],"published-print":{"date-parts":[[2024,12,31]]},"DOI":"10.1080\/21645515.2024.2397219","type":"journal-article","created":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T18:57:37Z","timestamp":1725994657000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":9,"title":["Human papillomavirus (HPV) vaccination in a privately funded program in Ghana: A qualitative case study"],"prefix":"10.1080","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9654-404X","authenticated-orcid":false,"given":"Emmanuel","family":"Marfo","sequence":"first","affiliation":[{"name":"University of Alberta","place":["Edmonton, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bukola","family":"Salami","sequence":"additional","affiliation":[{"name":"University of Calgary","place":["Calgary, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Adjei","sequence":"additional","affiliation":[{"name":"University of Ghana","place":["Legon, Ghana"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"MacDonald","sequence":"additional","affiliation":[{"name":"University of Alberta","place":["Edmonton, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,9,10]]},"reference":[{"key":"e_1_3_9_2_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2023.1128717"},{"key":"e_1_3_9_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1917338"},{"key":"e_1_3_9_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djab080"},{"key":"e_1_3_9_5_1","unstructured":"GAVI. Ghana to vaccinate girls against HPV with GAVI support. 2024 [accessed 2024 Mar 27]. https:\/\/www.gavi.org\/news\/media-room\/ghana-vaccinate-girls-against-hpv-gavi-support."},{"key":"e_1_3_9_6_1","doi-asserted-by":"publisher","DOI":"10.4314\/gmj.v52i2.6"},{"key":"e_1_3_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.07.027"},{"key":"e_1_3_9_8_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0240657"},{"key":"e_1_3_9_9_1","unstructured":"National Health Insurance Authority. Benefits package. 2024. https:\/\/www.nhis.gov.gh\/benefits."},{"key":"e_1_3_9_10_1","unstructured":"United Nations. Nigeria to vaccinate 7.7 million girls against leading cause of cervical cancer. Published 2023 [accessed 2024 Apr 6]. https:\/\/unsdg.un.org\/latest\/stories\/nigeria-vaccinate-77-million-girls-against-leading-cause-cervical-cancer."},{"key":"e_1_3_9_11_1","unstructured":"TV3 News. Nationwide vaccination against human papilloma virus to begin by close of year \u2013 Ghana health service. 2024 [accessed 2024 Mar 27]. https:\/\/3news.com\/health\/nationwide-vaccination-against-human-papilloma-virus-to-begin-by-close-of-year-ghana-health-service\/."},{"key":"e_1_3_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcpo.2020.100220"},{"key":"e_1_3_9_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12905-021-01296-3"},{"key":"e_1_3_9_14_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph17020571"},{"key":"e_1_3_9_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12912-020-00530-x"},{"key":"e_1_3_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.06.074"},{"key":"e_1_3_9_17_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01651"},{"key":"e_1_3_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.03.093"},{"key":"e_1_3_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2022.11.007"},{"key":"e_1_3_9_20_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11050890"},{"key":"e_1_3_9_21_1","volume-title":"Case study research and applications design and methods","author":"Yin RK","year":"2018","unstructured":"Yin RK. Case study research and applications design and methods. 6th ed. United States of America: SAGE Publications; 2018.","edition":"6"},{"key":"e_1_3_9_22_1","doi-asserted-by":"publisher","DOI":"10.1080\/17482631.2024.2315636"},{"issue":"1","key":"e_1_3_9_23_1","first-page":"1","article-title":"Demarginalizing the intersection of race and sex: a black feminist critique of antidiscrimination doctrine, feminist theory and antiracist politics","volume":"8","author":"Crenshaw K","year":"1989","unstructured":"Crenshaw K. Demarginalizing the intersection of race and sex: a black feminist critique of antidiscrimination doctrine, feminist theory and antiracist politics. Univ Chic Leg Forum. 1989;8(1):1\u201331. http:\/\/chicagounbound.uchicago.edu\/uclfhttp:\/\/chicagounbound.uchicago.edu\/uclf\/vol1989\/iss1\/8.","journal-title":"Univ Chic Leg Forum"},{"key":"e_1_3_9_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/phc3.12129"},{"key":"e_1_3_9_25_1","doi-asserted-by":"publisher","DOI":"10.1186\/1475-9276-12-14"},{"key":"e_1_3_9_26_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2019.1625642"},{"key":"e_1_3_9_27_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10020228"},{"key":"e_1_3_9_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10488-013-0528-y"},{"key":"e_1_3_9_29_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12912-022-00943-w"},{"key":"e_1_3_9_30_1","doi-asserted-by":"publisher","DOI":"10.1080\/2159676X.2019.1704846"},{"key":"e_1_3_9_31_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-13-117"},{"key":"e_1_3_9_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/s43586-022-00150-6"},{"key":"e_1_3_9_33_1","doi-asserted-by":"publisher","DOI":"10.7748\/nr.21.5.19.e1240"},{"key":"e_1_3_9_34_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13012-017-0605-9"},{"key":"e_1_3_9_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.puhip.2024.100505"},{"key":"e_1_3_9_36_1","doi-asserted-by":"publisher","DOI":"10.1177\/1833358320929776"},{"key":"e_1_3_9_37_1","doi-asserted-by":"publisher","DOI":"10.1177\/1049732316654870"},{"key":"e_1_3_9_38_1","doi-asserted-by":"publisher","DOI":"10.1097\/ACM.0000000000000388"},{"issue":"4","key":"e_1_3_9_39_1","first-page":"344","article-title":"Recommended solutions to the barriers to immunization in children and adults center for vaccine development","volume":"111","author":"Anderson EL","year":"2014","unstructured":"Anderson EL. Recommended solutions to the barriers to immunization in children and adults center for vaccine development. Mo Med. 2014;111(4):344\u2013348. www.cdc.gov\/vaccines\/vac-en\/6mishome.","journal-title":"Mo Med"},{"key":"e_1_3_9_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s44250-023-00044-8"},{"key":"e_1_3_9_41_1","doi-asserted-by":"publisher","DOI":"10.1080\/19312458.2018.1453057"},{"key":"e_1_3_9_42_1","unstructured":"Centers for Disease Control and Prevention. HPV vaccine information for young women."},{"key":"e_1_3_9_43_1","unstructured":"Cox TJ Palefsky JM. Human papillomavirus vaccination. UpToDate. Published 2024. https:\/\/www.uptodate.com\/contents\/human-papillomavirus-vaccination\/printwww.uptodate.com."},{"key":"e_1_3_9_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2015.146"},{"key":"e_1_3_9_45_1","unstructured":"National Advisory Committee on Immunization (NACI). Updated recommendations on human papillomavirus (HPV) vaccines: 9-valent HPV vaccine and clarification of minimum intervals between doses in the HPV immunization schedule. 2017 [accessed 2024 Mar 27]. https:\/\/www.canada.ca\/content\/dam\/hc-sc\/healthy-canadians\/migration\/publications\/healthy-living-vie-saine\/human-papillomavirus-9-valent-vaccine-update-recommendation-mises-a-jour-recommandations-papillome-humain-vaccin-nonavalent\/alt\/hpv-phv-eng.pdf."},{"key":"e_1_3_9_46_1","doi-asserted-by":"publisher","DOI":"10.4103\/jpdtsm.jpdtsm_136_23"},{"key":"e_1_3_9_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/rfc2.24"},{"key":"e_1_3_9_48_1","doi-asserted-by":"publisher","DOI":"10.31557\/APJCP.2022.23.6.1901"},{"key":"e_1_3_9_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/bioe.12771"},{"key":"e_1_3_9_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.06.060"},{"key":"e_1_3_9_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.12.067"},{"key":"e_1_3_9_52_1","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2018.1411195"},{"key":"e_1_3_9_53_1","unstructured":"International Vaccine Access Center (IVAC). One dose at a time: mobilizing to eliminate cervical cancer in Nigeria. Published 2024. https:\/\/publichealth.jhu.edu\/ivac\/2024\/one."},{"key":"e_1_3_9_54_1","unstructured":"International Vaccine Access Center (IVAC). HPV vaccine progress and next steps for advocacy in Ghana: findings from key informants. 2023 [accessed 2024 Mar 27]. https:\/\/publichealth.jhu.edu\/sites\/default\/files\/2024-02\/hpv-vaccine-advocacy-in-ghanaivac2023ax.pdf."},{"key":"e_1_3_9_55_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-019-7120-7"},{"key":"e_1_3_9_56_1","doi-asserted-by":"publisher","DOI":"10.1111\/tct.13762"}],"container-title":["Human Vaccines & Immunotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/21645515.2024.2397219","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T13:19:28Z","timestamp":1744636768000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/21645515.2024.2397219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,10]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,12,31]]}},"alternative-id":["10.1080\/21645515.2024.2397219"],"URL":"https:\/\/doi.org\/10.1080\/21645515.2024.2397219","relation":{},"ISSN":["2164-5515","2164-554X"],"issn-type":[{"value":"2164-5515","type":"print"},{"value":"2164-554X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,10]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=khvi20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=khvi20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-05-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-09","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"2397219"}}